Prevention & lipidsResearch article

Effectiveness and safety of treatment for heterozygous familial hypercholesterolaemia and multifactorial dyslipidaemia in children: an overview of systematic reviews

Eur J Prev CardiolPublished

  • Overview of systematic reviews
  • AMSTAR-2 appraisal
  • GRADE certainty of evidence

Authors' conclusion

In summary, statins are effective lipid-lowering therapy in paediatric FH, with long-term safety requiring further investigation.

Study context

Population
Children with heterozygous familial hypercholesterolaemia (heFH) or multifactorial dyslipidaemia (MFD)8 systematic reviews (SRs)
Comparison
Lipid-lowering treatments vs placebo or control in children

Main finding

LDL-C, statins vs placebo in heFH · 2-year follow-up

MD

−32.15 %

95% CI −34.9 to −29.4

Statins vs Placebo
MD −32.15 % (95% CI −34.9 to −29.4)

As reported in the abstract

Further findings

OutcomeMD (mg/dL) (95% CI)
LDL-C, ezetimibe (heFH) · 1 RCT, n = 127−63 (−79.5 to −46.5)
OutcomeMD in change (%)
LDL-C change, PCSK9 inhibitors (heFH) — Evolocumab vs Placebo · 1 RCT, n = 157 · moderate CoE−43.3
LDL-C change, PCSK9 inhibitors (heFH) — Alirocumab vs Placebo · 1 RCT, n = 153 · moderate CoE−33.8

Bile acid sequestrants and fibrates

Significant lipid-lowering effects; Certainty of evidence (CoE) low/very low

Non-pharmacological interventions (paediatric FH)

Mainly did not improve lipid profile (CoE very low)

Behavioural counselling (MFD)

Modest lipid-lowering effects that attenuated over time (2 randomized controlled trials (RCTs); low CoE)

Safety

Adverse events, short-term follow-up

No significant differences between groups for all drugs

Original publication

Effectiveness and safety of treatment for heterozygous familial hypercholesterolaemia and multifactorial dyslipidaemia in children: an overview of systematic reviews. Eur J Prev Cardiol. Published 30 March 2026. doi:10.1093/eurjpc/zwag125

Summarised from the published abstract; every number is checked against it